Please ensure Javascript is enabled for purposes of website accessibility

Here's Why bluebird bio's Shares Soared 24% in November

By Todd Campbell - Dec 7, 2017 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's making significant progress on a pipeline that could generate billions of dollars in sales someday.

What happened

After bluebird bio (BLUE 2.60%) updated investors on the presentations it will be making at a key industry conference soon, its shares jumped 24.2% in November, according to S&P Global Market Intelligence

So what

The company is on the cutting edge of gene-therapy research, and in November, management unveiled data that it will be presenting this month at the high-profile American Society of Hematology conference, which runs from December 9 to December 12.

Business people cheer on a beach.

IMAGE SOURCE: GETTY IMAGES.

Investigators will discuss updated results for bluebird bio's LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease. They'll also update data for bb2121, their investigational chimeric antigen receptor T-cell therapy (CAR-T) for late-stage multiple myeloma. 

Transfusion-dependent beta thalassemia is a rare and severe genetic blood disease requiring lifelong supportive care, blood transfusions, and chelation treatments that remove heavy metals. These patients can suffer organ damage from the disease and iron overload, so there's an important need for new treatment approaches beyond allogeneic hematopoietic stem cell transplant (HSCT). HSCT can treat the underlying cause of beta-thalassemia, but it exposes patients to risks, including treatment-related mortality, graft failure, graft versus host disease, and infection.

The need for new treatments for sickle-cell disease is big, too. Patients with severe sickle-cell disease face anemia, vaso-occlusive crisis, infections, stroke, and sometimes, early death. Currently, treatment centers on preventing infection and disease management, which may include hydroxyurea drugs and, in certain cases, regular transfusions. HSCT can be used in these patients, too, but it still carries the same risks as in beta-thalassemia.

In addition to listening in to what bluebird bio has to say about LentiGlobin's safety and efficacy in those two important indications, industry watchers will also be listening carefully to the update provided for bb2121.

In June, bluebird bio stole the show at the American Society of Clinical Oncology conference when it reported that bb2121 delivered a 100% response rate in evaluable, heavily pre-treated, multiple myeloma patients. It's likely that response rates will slip over time, as more patients are evaluated, but it appears that the trial was a success given that bluebird bio's collaboration partner, Celgene (CELG) is set to begin enrolling patients in a phase 2 trial soon that could allow for an accelerated Food and Drug Administration approval.

Now what

Gene therapy is a major advance in patient treatment, and bluebird bio's therapies have the potential to reshape patient standard of care in these indications. It's anyone's guess if data presented at the ASH conference will be confirmed in larger studies that can enable regulatory approvals, but there's good reason for industry watchers and investors to be buzzing and hopeful. After all, if these therapies are effective and safe, they could generate billions of dollars in combined sales -- if they eventually make it to market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$4.14 (2.60%) $0.10
Celgene Corporation Stock Quote
Celgene Corporation
CELG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.